HCMT
BOLD

Highland Capital Management (Texas)’s Audentes Therapeutics, Inc BOLD Stock Holding History

Highland Capital Management (Texas)’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-16,500
Closed -$516K – 394
2017
Q4 		$516K Sell
16,500
-5,500
-25% -$151K 0.02% 206
2017
Q3 		$616K Buy
+22,000
New +$478K 0.03% 208

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Highland Capital Management (Texas)'s BOLD Position: Q1 2018 in Review

Highland Capital Management (Texas) sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2018, closing a stake of 16,500 shares — an estimated $516K sold.

Highland Capital Management (Texas) first reported a position in BOLD in Q3 2017 and held it in 2 quarters. The position peaked at $616K in Q3 2017. 114 funds tracked by Wall St. Rank hold BOLD as of Q1 2018.

  • Highland Capital Management (Texas) reported no remaining Audentes Therapeutics, Inc position as of Q1 2018 after selling out during the quarter.
  • Highland Capital Management (Texas) sold 16,500 Audentes Therapeutics, Inc shares in Q1 2018, an estimated $516K.
  • Highland Capital Management (Texas) first reported a position in Audentes Therapeutics, Inc in Q3 2017 and held it in 2 quarters.
  • Highland Capital Management (Texas)'s Audentes Therapeutics, Inc position peaked at $616K in Q3 2017.
  • 114 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2018.

Based on Highland Capital Management (Texas)'s 13F filing for Q1 2018, filed 15 May 2018.